innerbuddies gut microbiome testing

Gut Microbiome & Infant Eczema: Probiotics for Atopic Dermatitis

Infant and pediatric atopic dermatitis (eczema) is more than a skin issue—research increasingly points to a “gut-skin axis,” where the developing gut microbiome can influence immune balance, skin barrier function, and inflammatory signaling. In early life, the gut ecosystem is still forming, and variations in microbial diversity and strain composition have been associated with higher eczema risk and differences in disease severity.

The connection is thought to work through immune education. Gut microbes help train the infant’s immune system to respond appropriately to environmental triggers. When the microbiome is less diverse or dominated by certain patterns, immune responses can skew toward inflammation. That inflammatory tendency may contribute to the cycle of itchy, irritated skin and a weakened skin barrier—both hallmarks of atopic dermatitis.

Probiotics have become a key area of interest because they may support a healthier microbial balance during this critical window of development. The goal isn’t a “one-size-fits-all” approach—emerging evidence suggests that specific probiotic strains (and sometimes combinations) may help modulate immune markers and promote a more favorable gut environment that, in turn, supports skin health. Understanding which strains are studied for eczema and what parents should look for in probiotic options is essential for making informed choices.

Get a Gut Microbiome Test for Infant Eczema Get a Gut Microbiome Test Subscription for Infant/Child Eczema Support
innerbuddies gut microbiome testing

Infant / pediatric atopic dermatitis

Infant and pediatric atopic dermatitis is discussed with emphasis on the gut–skin axis. The developing gut microbiome in early life can influence immune maturation and skin barrier function, potentially shaping eczema risk and severity through regulatory pathways and microbial metabolites like short-chain fatty acids. Probiotics and targeted nutrition are explored as adjunct strategies to support immune regulation and barrier integrity, rather than as cures for the condition.

Common microbiome patterns in eczema include lower levels of beneficial taxa such as Bifidobacterium longum and B. breve; Faecalibacterium prausnitzii, Roseburia, Anaerostipes, Akkermansia muciniphila, Subdoligranulum, and Coprococcus; while elevated taxa include Staphylococcus (S. aureus), Escherichia-Shigella, Klebsiella, Streptococcus, Bacteroides with enterotoxin profiles, and pathobiont-associated Clostridium sensu stricto. These shifts may impact gut barrier function and promote pro-inflammatory immune signaling, contributing to persistent or recurrent flares such as dry, itchy patches.

microbiome testing is proposed as a way to personalize adjunct strategies—selecting probiotics, prebiotics, and dietary changes based on an individual’s gut profile and monitoring response over time. The InnerBuddies test is described as a tool to clarify gut–skin axis involvement and guide targeted interventions to improve immune regulation and barrier resilience, aiming to reduce eczema activity and improve quality of life rather than provide a cure.

  • S. aureus dominance in infants with atopic dermatitis is linked to more severe flares through skin barrier disruption and pro-inflammatory signaling.
  • Butyrate-producing taxa (Faecalibacterium prausnitzii, Roseburia, Anaerostipes, Subdoligranulum, Coprococcus) support regulatory T-cell–mediated tolerance and strengthen the gut barrier, which can reduce eczema severity.
  • Bifidobacterium species (e.g., B. longum, B. breve) promote anti-inflammatory signaling and barrier integrity, potentially aiding immune tolerance in infancy.
  • Akkermansia muciniphila enhances mucin layer integrity and gut barrier function, which may decrease systemic inflammatory cues that worsen skin symptoms.
  • SCFA-driven immune-metabolic signaling (butyrate, propionate) from gut microbes can modulate skin inflammation and support epidermal barrier proteins, reducing itch and flares.
  • Dysbiotic patterns with elevated taxa such as Escherichia-Shigella, Klebsiella, Streptococcus, and enterotoxigenic Bacteroides are linked to higher inflammatory tone and more persistent eczema.
  • Early-life gut microbiome diversity and balance influence immune tolerance programming via the gut–skin axis, helping explain variable eczema trajectories and guiding targeted probiotic/nutrition strategies.
Get a Gut Microbiome Test for Infant Eczema Get a Gut Microbiome Test Subscription for Infant/Child Eczema Support
innerbuddies gut microbiome testing

Atopic dermatitis / eczema

Atopic dermatitis (often called infant eczema) is a common inflammatory skin condition that typically begins in early life and can be driven by a mix of genetic susceptibility, skin barrier immaturity, immune dysregulation, and environmental exposures. In recent years, research has increasingly highlighted the gut-skin axis—the idea that the developing gut microbiome can influence immune responses that affect the skin. During infancy, microbial communities are still forming, making this a sensitive window where early gut colonization patterns may affect how strongly the immune system “learns” to tolerate harmless environmental antigens versus overreacting in allergic and inflammatory pathways.

Gut microbial diversity and balance may contribute to eczema risk through several interconnected mechanisms. Certain gut bacteria are thought to support regulatory immune pathways (such as increased production of anti-inflammatory signaling molecules) and help maintain a healthier intestinal barrier, which can reduce systemic inflammation signals that may worsen skin inflammation. Conversely, an altered microbiome—sometimes associated with lower microbial diversity or a skewed composition—has been reported in some infants with eczema. While not every child with eczema has the same microbiome pattern, these findings help explain why targeted nutritional strategies, including probiotic supplementation, are being studied as potential adjuncts to standard eczema care.

Probiotics—live microorganisms that may confer health benefits when provided in adequate amounts—are of particular interest because specific strains may help promote a more favorable immune environment and gut barrier function. For infants and pediatric patients, the goal is not to “cure” eczema, but potentially to support healthier immune regulation and reduce inflammatory propensity, especially in those with early or persistent symptoms. When considering probiotic options, parents and clinicians often focus on evidence from randomized trials for particular strains and dosages, product quality (strain identification and viable counts through the end of shelf life), and safety for the child’s age and health status—particularly in infants who are premature, immunocompromised, or critically ill. Overall, the gut-skin connection is a promising area, and ongoing research continues to refine which probiotic strains, timing, and subgroups may benefit most for infant atopic dermatitis.

  • Dry, itchy skin (eczema flares often worsen at night)
  • Red, inflamed patches of skin
  • Rough, scaly or thickened skin over time
  • Swelling and tenderness in affected areas
  • Crusting, oozing, or weeping from inflamed lesions (especially during flares)
  • Persistent or recurrent eczema affecting typical sites (face, scalp, cheeks, trunk, and flexural areas)
Get a Gut Microbiome Test for Infant Eczema Get a Gut Microbiome Test Subscription for Infant/Child Eczema Support
innerbuddies gut microbiome testing

Infant / pediatric atopic dermatitis

This is relevant for infants and pediatric patients with atopic dermatitis (often called infant eczema), especially those whose eczema begins early in life and tends to recur or persist. It may be particularly applicable when symptoms show an inflammatory pattern—such as dry, itchy skin with frequent flares—where families are exploring additional, gut-focused supportive approaches alongside standard skin care.

It also fits children whose caregivers are interested in the “gut-skin axis,” the emerging concept that early-life gut microbiome development can influence immune regulation and the tendency toward skin inflammation. This includes families looking to understand whether differences in gut microbial diversity or composition during infancy could contribute to eczema severity, immune overreaction, or difficulty maintaining a stable skin barrier—factors reflected in symptoms like redness, rough/scaly patches, and thickened skin over time.

Consider it especially relevant for pediatric cases with ongoing symptoms such as persistent or recurrent eczema affecting common sites (face, scalp, cheeks, trunk, and flexural areas), including episodes with swelling, tenderness, or weeping/crusting during flares. Caregivers of infants should also pay attention to age- and health-specific suitability (e.g., premature infants, immunocompromised children, or critically ill patients) when discussing probiotic options with clinicians, since safety and strain-specific evidence matter.

Atopic dermatitis (infant eczema) is one of the most common inflammatory skin conditions in childhood. It typically begins in early life, and a large proportion of cases present during infancy, often starting with dry, itchy skin and evolving into recurrent red, inflamed patches that may weep or crust during flares. Overall, epidemiologic studies across regions consistently show that eczema affects a substantial minority of children, with prevalence estimates often in the ~15–20% range globally, and higher rates reported in some countries and urban populations.

Prevalence is especially high during the first years of life, aligning with the early developmental timing emphasized by the gut–skin axis concept. Many children experience symptoms such as night-worsening itch, persistent or recurrent eczematous lesions on typical sites (face, scalp, cheeks, trunk, and flexural areas), and progressive thickening or scaling over time. Because the condition can be chronic or relapsing, the overall “lifetime prevalence” in childhood is often greater than point estimates measured at a single age.

In terms of how widespread it is within pediatric care, atopic dermatitis is a leading reason families seek dermatology and allergy-related services. While individual severity varies widely—from mild dry, scaly skin to more extensive inflammation with swelling, tenderness, and oozing/crusting—community-based data generally support that roughly 1 in 5 children are affected at some point. This high prevalence makes eczema a major target for supportive strategies, including those exploring the gut microbiome’s role in immune regulation and barrier function.

Get a Gut Microbiome Test for Infant Eczema Get a Gut Microbiome Test Subscription for Infant/Child Eczema Support
innerbuddies gut microbiome testing

Gut Microbiome & Infant Eczema: How Probiotics May Support Atopic Dermatitis

Atopic dermatitis in infants and children has been increasingly linked to the gut microbiome through the “gut-skin axis.” Early in life, the microbiome is still developing, and the balance of gut microbes can influence how the immune system matures—shifting immune responses toward tolerance of harmless environmental triggers or, in some infants, toward more inflammation-prone pathways. This immune programming can affect skin barrier function and inflammatory signaling, helping explain why some children experience persistent or recurrent eczema flares.

Research suggests that differences in gut microbial diversity and composition are reported in subsets of infants with eczema. Some bacteria are thought to support regulatory immune processes (e.g., anti-inflammatory signaling) and help maintain gut barrier integrity, which may reduce systemic inflammatory cues that can worsen skin inflammation. When the microbiome is altered—sometimes described as lower diversity or an imbalanced community—immune regulation may be less effective, potentially increasing the likelihood or severity of eczema flares and common symptoms like red, inflamed patches and intense itch.

Because eczema often involves flares characterized by dryness, itching (often worse at night), and, in some cases, weeping or crusting lesions, the gut-skin connection has spurred interest in nutritional and probiotic strategies as adjuncts to standard skin care. The goal is not to “cure” eczema, but to support more favorable immune regulation and gut barrier function using specific probiotic strains studied for pediatric safety and efficacy. Ongoing research continues to refine which strains, doses, and timing may be most beneficial for early-onset or persistent atopic dermatitis.

Get a Gut Microbiome Test for Infant Eczema Get a Gut Microbiome Test Subscription for Infant/Child Eczema Support
innerbuddies gut microbiome testing

Gut Microbiome and Infant / pediatric atopic dermatitis

  • Immune tolerance programming via early-life microbiome: Gut microbes shape developing immune responses (e.g., regulatory T-cell pathways) that determine whether the body tolerates harmless antigens or shifts toward pro-inflammatory signaling linked to eczema flares.
  • Gut barrier integrity and reduced systemic inflammation: Beneficial microbes help maintain intestinal barrier function; when barrier integrity is weaker, translocation of microbial products can increase systemic inflammatory cues that worsen skin inflammation.
  • Microbial metabolite signaling to the immune system: Fermentation-derived short-chain fatty acids (e.g., butyrate, propionate) and other metabolites can modulate inflammatory pathways and strengthen immune regulation, influencing itch and lesion severity.
  • Microbiome-driven regulation of skin barrier function: Immune and cytokine signals originating from the gut can affect epidermal barrier-related processes (e.g., filaggrin expression and stratum corneum integrity), altering susceptibility to dryness and inflammation.
  • Altered gut microbial diversity and dysbiosis effects: Reduced diversity or imbalanced microbial composition has been observed in subsets of children with atopic dermatitis, potentially leading to less effective immune regulation and heightened inflammatory tone.
  • Vagal and endocrine communication between gut and skin (gut–skin axis): Neural and hormone-mediated signaling can transmit immune-metabolic status from the gut to peripheral tissues, contributing to synchronized inflammatory responses in the skin.
  • Influence on allergy-related sensitization and Th2-skewing: Certain microbial patterns may promote or dampen Th2/eosinophilic immune responses; a more pro-allergic immune profile can increase risk of persistent eczema and itch-driven flares.

In infants and children with atopic dermatitis, the gut microbiome can influence how the immune system “learns” to react early in life—a concept often described as immune tolerance programming through the gut–skin axis. During infancy, gut microbial communities are still developing, and their composition can affect immune pathways such as regulatory T-cell activity. When the microbiome supports more balanced immune regulation, the body may be better able to tolerate harmless environmental triggers; when microbial patterns shift toward a more inflammation-prone profile, immune signaling can become skewed toward pro-inflammatory responses that contribute to persistent eczema flares.

A second mechanism involves gut barrier integrity and downstream inflammatory signaling. Beneficial gut microbes help maintain intestinal barrier function; when that barrier is weaker, microbial components and inflammatory cues may cross more easily into circulation, raising systemic inflammation that can worsen skin symptoms. Atopic dermatitis often presents with dryness, intense itch (commonly worse at night), and inflamed patches; gut-driven increases in inflammatory tone and cytokine signaling can intensify these skin responses and prolong flare cycles. Additionally, gut microbes produce metabolites—especially short-chain fatty acids such as butyrate and propionate—that can directly modulate immune function and strengthen regulatory pathways, potentially reducing itch and lesion severity.

Microbiome-driven immune-metabolic signals may also affect the skin barrier itself and influence allergy-related immune sensitization. Metabolites and immune mediators originating in the gut can alter skin-related processes linked to barrier resilience, such as pathways involved in epidermal integrity and protein expression (e.g., filaggrin-related mechanisms). Meanwhile, differences in microbial diversity—sometimes described as reduced diversity or dysbiosis—have been observed in subsets of children with eczema, and certain microbial patterns may promote or dampen Th2-skewed, allergy-associated immune responses. Through immune, neural (vagal), and endocrine communication between gut and skin, these gut-derived signals can coordinate inflammation and barrier dysfunction, increasing susceptibility to recurrent eczema flares.

Get a Gut Microbiome Test for Infant Eczema Get a Gut Microbiome Test Subscription for Infant/Child Eczema Support
innerbuddies gut microbiome testing

Microbial patterns summary

In infants and children with atopic dermatitis, studies often report gut microbiome differences compared with healthy peers, particularly in early life when microbial ecosystems are still maturing. A common theme is reduced microbial diversity and altered community composition, meaning the balance between beneficial commensal bacteria and other taxa is shifted. These changes are thought to affect how the immune system “learns” tolerance during infancy, including regulatory pathways linked to anti-inflammatory signaling and reduced sensitivity to harmless environmental triggers. When the developing gut community is less supportive of immune regulation, immune responses can tilt more toward pro-inflammatory patterns that correlate with more persistent or recurrent eczema flares.

Beyond overall diversity, researchers frequently describe microbiome imbalances that may influence intestinal barrier integrity and downstream inflammation. Some microbial profiles are associated with weaker gut barrier function, allowing microbial products and inflammatory cues to be more likely to reach systemic circulation. That systemic inflammatory tone can, via immune signaling pathways that communicate gut to skin, worsen the characteristic eczema features—red, inflamed patches, intense itch (often worse at night), and cycles of flare and repair. In contrast, gut communities enriched in microbes that support barrier resilience are hypothesized to reduce inflammatory “background noise,” helping immune signals remain better regulated and potentially lowering the severity or frequency of flares.

Metabolite-driven immune effects are another key pattern linked to pediatric atopic dermatitis. Beneficial gut bacteria can produce short-chain fatty acids (including butyrate and propionate), which act as immune modulators and support regulatory T-cell activity. Lower levels or altered availability of these metabolites—often reflecting dysbiosis—may reduce regulatory signaling and contribute to higher pro-inflammatory cytokine activity that amplifies skin inflammation. These gut-derived immune-metabolic cues may also connect to skin barrier biology, influencing pathways relevant to epidermal integrity and sensitization, and thereby shaping flare susceptibility and recovery in children with atopic dermatitis.


Low beneficial taxa

  • Bifidobacterium (e.g., B. longum, B. breve)
  • Faecalibacterium prausnitzii
  • Roseburia (butyrate-producing taxa)
  • Anaerostipes (butyrate-producing taxa)
  • Akkermansia muciniphila
  • Subdoligranulum (SCFA-associated taxa)
  • Coprococcus (SCFA-associated taxa)


Elevated / overrepresented taxa

  • Staphylococcus (including S. aureus associated strains)
  • Escherichia-Shigella
  • Klebsiella
  • Streptococcus
  • Bacteroides (various species, esp. enterotoxin-producing/less beneficial profiles)
  • Clostridium sensu stricto (pathobiont-associated Clostridia)


Functional pathways involved

  • Short-chain fatty acid (SCFA) biosynthesis and cross-feeding (e.g., butyrate/propionate production; downstream Treg-supporting immune signaling)
  • Tryptophan metabolism via aryl hydrocarbon receptor (AhR) signaling (regulates mucosal/immune tolerance that can affect atopic inflammation)
  • Bile acid transformation and FXR/TGR5-mediated immune effects (modulates intestinal barrier integrity and inflammatory set-point)
  • Intestinal barrier maintenance pathways (mucin/glycan utilization, tight-junction and epithelial integrity programs; influenced by taxa such as Akkermansia)
  • Microbial-derived innate immune activation (LPS/endotoxin and other microbial product–driven pattern recognition receptor signaling such as TLR/NLR pathways)
  • Regulatory immune pathway modulation (Treg/anti-inflammatory cytokine induction such as IL-10, impaired by dysbiosis and reduced SCFAs)
  • Pro-inflammatory microbial metabolite and toxin pathway signaling (e.g., enterotoxin- or pathobiont-associated metabolites that promote systemic inflammatory tone)
  • Microbial dysbiosis–associated oxidative stress and epithelial stress responses (reactive oxygen/nitrogen signaling that worsens barrier function and flare susceptibility)


Diversity note

In infants and children with atopic dermatitis, gut microbiome studies commonly find differences from healthy peers during early life, when the microbial ecosystem is still maturing. A recurring theme is reduced overall microbial diversity and a shift in community composition, reflecting an imbalance between typically beneficial commensal groups and other taxa that may be more pro-inflammatory. Because early-life microbial signals help “train” the immune system toward tolerance, these diversity and compositional changes may be associated with a higher tendency for immune dysregulation that can track with ongoing or recurrent eczema flares.

Beyond diversity alone, dysbiosis patterns seen in pediatric eczema are often linked to weaker gut barrier integrity and altered immune crosstalk. When the intestinal lining is less resilient, microbial products and inflammatory cues may cross into the systemic circulation more easily, increasing the background immune activation that can worsen skin inflammation. This may help explain why some children experience more persistent redness, itching (often worse at night), and cycles of flare-and-recovery, even when skin care is optimized.

Metabolite patterns frequently reinforce this connection: lower availability or altered production of immune-modulating metabolites (notably short-chain fatty acids such as butyrate and propionate) is often reported alongside dysbiosis. These metabolites support regulatory immune pathways (including regulatory T-cell activity) and help dampen pro-inflammatory signaling. When microbial diversity and metabolite output are reduced, regulatory tone may be less effective, allowing pro-inflammatory cytokine activity to rise and potentially amplifying the severity and frequency of atopic dermatitis symptoms.


Get a Gut Microbiome Test for Infant Eczema Get a Gut Microbiome Test Subscription for Infant/Child Eczema Support

Why generic solutions fail

  • Issue with generic solutions

    Generic solutions often fail for infant and pediatric atopic dermatitis because eczema flares are not driven by a single “cause” that responds uniformly to broad gut-health messaging. The gut microbiome develops rapidly in early life, and the immune system is actively learning tolerance during this window. A general probiotic or generic “healthy gut” approach may not address the specific pattern of dysbiosis seen in subsets of children with eczema—such as reduced microbial diversity, altered community balance, and downstream differences in gut barrier function and immune regulation.

    Many children also differ in baseline diet, delivery method (vaginal vs. C-section), antibiotic exposure, feeding type (breastfeeding vs. formula), and the presence of gastrointestinal symptoms. These factors can shift which microbes successfully colonize and which immune-metabolic pathways are most relevant. Without tailoring by strain specificity, dose, and timing to the child’s developmental stage and microbiome context, generic interventions may offer little signal for regulatory T-cell activity, short-chain fatty acid production (e.g., butyrate/propionate), or reduction in pro-inflammatory “background noise” that can aggravate skin inflammation.

    Finally, eczema severity and flare behavior reflect interactions between the gut-skin axis and the skin barrier itself (which can already be compromised), so improvements in gut markers don’t automatically translate into fewer flares. Generic products often lack evidence tied to pediatric atopic dermatitis, and they may not be durable enough to meaningfully change metabolite profiles or barrier integrity. As a result, families may see inconsistent or short-lived effects—especially when interventions don’t match the underlying microbial/metabolite deficits that are most likely to influence itch, redness, and persistent inflammation.

  • Common mistakes

    • Using broad “gut health” messaging or one-size-fits-all probiotic blends without matching the child’s likely dysbiosis pattern (e.g., reduced diversity vs. specific community shifts).
    • Ignoring early-life developmental timing: recommending interventions without considering when the infant/pediatric gut microbiome is actively maturing and when immune tolerance learning is most sensitive.
    • Assuming any probiotic is beneficial regardless of strain, dose, and duration; failing to target strains shown to support regulatory immune pathways and short-chain fatty acid (SCFA) production.
    • Not accounting for key confounders that strongly shape colonization and metabolite output (delivery mode, breastfeeding vs. formula, antibiotic exposure, and baseline diet).
    • Overlooking gut barrier and metabolite mechanisms: focusing on stool frequency or generic “regularity” rather than markers linked to barrier resilience and SCFA-mediated immune regulation (e.g., butyrate/propionate-related signaling).
    • Failing to stratify by GI symptom burden or comorbidities (e.g., cow’s milk protein intolerance, reflux, constipation), which can determine which microbial/metabolic routes are actually relevant to eczema flares.
    • Expecting direct eczema improvement from generic microbiome changes; not recognizing that skin barrier dysfunction and eczema triggers can sustain flares even if gut markers improve.
    • Using interventions that are not evidence-aligned for pediatric atopic dermatitis (lack of age-appropriate, eczema-specific clinical data) or using them for too short a period to durably alter community function.

What to do

  • General support strategies

    In infants and children with atopic dermatitis, growing evidence points to the “gut-skin axis,” where the developing gut microbiome helps shape early immune programming. During the first years of life, shifts in gut microbial diversity and composition may influence how the immune system balances tolerance versus inflammation. When immune regulation is less effectively “trained,” skin barrier function and inflammatory signaling can be more vulnerable, which may contribute to recurrent or persistent eczema flares, marked by itchy, red patches and disrupted skin comfort—often worse at night.

    Support strategies often focus on promoting a healthier intestinal environment alongside standard eczema care. Maintaining gut barrier integrity and encouraging regulatory (anti-inflammatory) immune pathways are common nutritional goals in this area. Approaches may include ensuring an overall nutrient-sufficient diet for the child, supporting healthy feeding patterns, and—when appropriate for pediatric age and safety—using targeted probiotic strains that have been studied for atopic dermatitis outcomes. The aim is not to replace topical or medical management, but to complement it by helping the immune system respond more calmly to everyday environmental triggers.

    Timing and strain selection matter because early-onset eczema involves a window when the microbiome is still maturing. Some probiotic protocols are designed to be started in infancy or used consistently through flares, with the expectation that gradual microbiome support can influence inflammatory tone over time. As research continues to refine the most effective strains, doses, and study designs for pediatric atopic dermatitis, families are typically advised to coordinate any probiotic or nutrition additions with their child’s clinician—especially for infants with severe disease or underlying medical conditions.

  • Lifestyle recommendations

    • Maintain a consistent, gentle skin-care routine: bathe with lukewarm water, use fragrance-free cleansers, moisturize at least twice daily (especially after bathing) to support the skin barrier.
    • Use eczema flare–friendly daily habits: keep nails short, dress in soft breathable fabrics, and manage itch (e.g., cool compresses) to reduce scratching and secondary inflammation.
    • Support healthy gut microbiome development through nutrition: encourage age-appropriate breastfeeding when possible and include a varied diet as solid foods are introduced (fiber-rich foods when age-appropriate).
    • Limit unnecessary dietary and environmental irritants: avoid known food triggers if they’ve been identified by a clinician, and minimize exposure to tobacco smoke and strong fragrances/harsh detergents.
    • Promote overall gut-skin immune support with regular sleep and stress reduction: ensure consistent sleep routines and calm daytime environments (for older children) to help reduce immune dysregulation that can worsen flares.
    • Consider clinician-guided probiotics or prebiotics only as an adjunct to standard care: if trying a probiotic, choose specific strains and dosing appropriate for infants/children under pediatric guidance.

  • Nutrition recommendations

    • Breastfeed exclusively for ~6 months when possible, and continue alongside complementary foods for up to 12 months or longer, as breast milk supports beneficial gut microbiota that may help immune tolerance in early life.
    • Use a pediatric-appropriate, fiber-rich diet after weaning (e.g., age-appropriate fruits/vegetables, oats, legumes where tolerated) to promote gut microbial diversity and production of short-chain fatty acids that support gut barrier and immune regulation.
    • Consider probiotic supplementation in consultation with the child’s clinician—prioritizing strains with pediatric eczema evidence (commonly Lactobacillus rhamnosus GG and/or Bifidobacterium species such as B. lactis)—especially for early-onset or recurrent flares.
    • Support prebiotic intake (e.g., age-appropriate foods containing inulin/FOS or well-tolerated alternatives) to feed beneficial gut microbes; avoid drastic changes and tailor to tolerance, especially in younger children.
    • Ensure adequate intake of anti-inflammatory nutrients, including omega-3 fatty acids (age-appropriate fatty fish or pediatric formulations) and vitamin D (from diet and/or medically guided supplementation if levels are low), as these may reduce inflammatory signaling that worsens eczema.
    • If food allergy is suspected or confirmed, manage it with a clinician/allergist rather than eliminating foods broadly; overly restrictive diets can reduce microbial diversity and may worsen nutritional status.

  • Supplement considerations

    For infants and children with atopic dermatitis, supplement considerations often focus on supporting the “gut-skin axis,” where early gut microbiome development may influence how the immune system matures and how strongly inflammatory pathways are activated. In some children, research has noted differences in gut microbial diversity and community composition compared with non-eczema peers, suggesting that reduced microbial diversity or an imbalanced microbiome may be associated with less effective immune regulation. Because immune programming in early life can affect skin barrier integrity and inflammatory signaling, nutrition and targeted microbial support are typically considered as adjuncts to standard eczema care—aiming to reduce flare frequency or severity rather than replacing topical therapy.

    Probiotic and prebiotic strategies are commonly discussed because certain gut microbes and their metabolites may support regulatory immune processes and help maintain gut barrier function, potentially lowering systemic inflammatory cues that can worsen skin symptoms. When considering supplements for pediatric atopic dermatitis, it’s generally important to choose products with specific, well-studied probiotic strains (rather than vague “probiotic blends”), with pediatric dosing appropriate for age and weight, and to evaluate tolerance and adherence over a trial period. Some families also explore dietary approaches that promote a healthier microbiome (for example, fiber- and polyphenol-containing foods when age-appropriate), since substrate availability can influence whether beneficial microbes thrive.

    Safety, timing, and realistic expectations matter. Supplements are not a substitute for core eczema management such as moisturization, trigger reduction, and clinician-guided use of anti-inflammatory treatments during flares. For infants, probiotic use should be approached carefully—especially in very young babies, preterm infants, or children with significant immune compromise—by confirming suitability with a pediatrician. Overall, the most evidence-informed approach is to select strain-specific options with pediatric safety data, start with appropriate dosing, monitor skin and gut symptoms over time, and discontinue or adjust if side effects occur.

  • Retesting / monitoring note

    For infant and pediatric atopic dermatitis, retesting is typically considered when symptoms persist, recur frequently, or change in pattern despite a consistent baseline approach to skin care. Because the gut-skin axis involves an evolving gut microbiome early in life, clinician-guided retesting may be timed after an adequate exposure window to any nutrition, probiotic, or dietary changes—often several weeks—so results reflect a meaningful shift in gut ecology and immune signaling rather than short-term variation.

    Retesting can also be helpful if there are new triggers (e.g., illness, antibiotic exposure, changes in feeding type, introduction of solids, or a flare that becomes more severe). In these situations, the developing microbiome and immune programming may be altered, and reassessment can support more targeted next steps—such as confirming adherence, adjusting strain/dose, or refining adjunct interventions aimed at promoting regulatory immune responses and supporting gut barrier integrity.

    Finally, retesting recommendations should account for ongoing eczema dynamics: improvement in itch and redness may take time, and flares are common in children. Where testing is used, it is most informative when interpreted alongside standardized clinical outcomes (severity scoring, sleep disruption, lesion distribution, and flare frequency) and standardizes timing relative to interventions. This approach helps distinguish true response trends from natural fluctuation and supports safer, evidence-aligned continuation or modification of gut-directed strategies.

The importance of gut microbiome testing

  • Why testing matters

    In infant and pediatric atopic dermatitis, the gut-skin axis suggests that what’s happening in the gut can influence immune tone and skin barrier function—both of which play major roles in eczema flare frequency and severity. Because early-life microbiomes are still developing, individual differences in microbial diversity and community balance may help explain why two children can experience very different eczema patterns, even with similar skin care. Gut microbiome testing can provide insight into these differences, potentially helping clinicians and caregivers understand whether an imbalanced microbiome—often discussed as lower diversity or reduced presence of beneficial, regulatory-supporting microbes—may be contributing to immune dysregulation that amplifies skin inflammation and itch.

    Testing also matters because it can guide more personalized adjunct strategies. Rather than using a one-size-fits-all approach, microbiome results may help identify patterns consistent with impaired gut barrier integrity or altered immune signaling (which can increase systemic inflammatory cues that worsen eczema). That context can make nutritional and probiotic interventions more targeted—supporting the goal of improving tolerance and regulatory immune pathways, not simply treating symptoms on the surface. For example, identifying specific deficits or shifts in microbial balance can support choosing interventions aligned with the child’s microbiome profile.

    Finally, microbiome testing can be useful for monitoring response over time. Since probiotics, prebiotics, feeding changes, antibiotics, and even illness can all affect gut microbial composition, tracking results can help determine whether an intervention is moving the microbiome in a more favorable direction. When changes align with improved eczema control—such as fewer inflamed patches, less weeping/crusting, and reduced nighttime itch—testing supports evidence-informed decision-making and helps refine what works for the individual child as their immune system and microbiome mature.

  • How InnerBuddies helps

    In infants and children with atopic dermatitis, the InnerBuddies test can help clarify whether gut microbiome patterns that relate to the “gut-skin axis” may be influencing immune tone and skin inflammation. Because early life microbiota are still developing, differences in microbial diversity and the balance of beneficial versus inflammation-associated communities can affect how the immune system matures and how robust the gut barrier is. When immune regulation is less effective, skin barrier disruption and inflammatory signaling can become more likely, contributing to recurring flares such as red, itchy patches—often worse at night—and, in some cases, weeping or crusting.

    By providing insight into the child’s gut microbial composition, InnerBuddies testing can support more personalized adjunct strategies alongside standard skin care. Instead of relying on a one-size-fits-all probiotic or nutrition approach, results may help identify microbiome features that are commonly discussed in the context of reduced regulatory support or impaired barrier function. This information can guide caregivers and clinicians toward interventions that are better aligned with the child’s current gut ecosystem—aiming to support immune tolerance and reduce systemic inflammatory cues that can worsen eczema.

    InnerBuddies can also be useful for monitoring change over time, since microbiome composition can shift with probiotics, prebiotics, diet changes, antibiotics, or intercurrent illness. Re-testing can help determine whether an intervention is moving the microbiome toward a pattern more commonly associated with improved immune regulation, and it can be connected to eczema outcomes such as fewer or less severe flares, reduced nighttime itch, and improved skin texture and hydration.

Medical Evidence

  • Scientific evidence level

    2 [weak / emerging but inconsistent]

  • Clinical relevance note

    Current clinical relevance is limited. While microbiome features differ on average between children with AD and controls and early-life microbial ecology may correlate with future AD risk, the findings are not sufficiently consistent, reproducible, or mechanistically specific to justify microbiome testing for diagnosis, risk stratification, or treatment selection in routine care. Most studies do not reach the standard required for validated clinical application: external validation is lacking, predictive models often do not generalize, and reported microbial signatures frequently fail to replicate across populations and platforms.

    From a treatment/prevention perspective, microbiome-targeted interventions (prebiotics/probiotics/synbiotics) show at best modest and inconsistent effects across trials, with considerable heterogeneity in strain selection, dosing, timing, populations, and endpoints. Importantly, even when clinical outcomes improve in some studies, it is rarely demonstrated that a specific microbiome change is the causal mediator of benefit (i.e., the microbiome is more of a correlate than a validated therapeutic target). Therefore, the microbiome is scientifically relevant to AD biology, but it is not yet an established, evidence-backed clinical tool for infant/pediatric AD management.

Title Journal Year Link
Gut microbiota and atopic dermatitis: A systematic review and meta-analysis Frontiers in Immunology 2023 View →
The gut microbiota in atopic dermatitis is impaired in diversity and function and is associated with disease severity Gut 2019 View →
Probiotics in prevention of atopic dermatitis in infants and young children: A meta-analysis of randomized controlled trials Pediatrics 2017 View →
Mode of delivery and early infant gut microbiota: Associations with atopic dermatitis The Journal of Allergy and Clinical Immunology 2017 View →
Early-life gut microbiome and risk of eczema in the first 2 years of life Clinical and Experimental Allergy 2008 View →

Frequently Asked Questions

    ¿Qué es la dermatitis atópica en la infancia y cuán común es?
    La dermatitis atópica en la infancia es una condición inflamatoria de la piel común; suele empezar en la primera infancia; la gravedad varía; se estima que alrededor del 15–20% de los niños la experimentan en algún momento.
    ¿Cómo influye el microbioma intestinal en la eczema en la primera infancia?
    El microbioma ayuda a la maduración del sistema inmunológico y la función de la barrera cutánea; ciertos patrones tempranos pueden influir en el riesgo y las exacerbaciones.
    ¿Qué es el eje intestino–piel, en términos simples?
    Las señales de los microbios intestinales pueden modular las respuestas inmunitarias y la inflamación de la piel.
    ¿Pueden los probióticos ayudar a mi bebé con la eczema y qué cepas tienen evidencia?
    Los probióticos pueden apoyar el equilibrio inmunológico y la función de la barrera intestinal; la evidencia depende de la cepa y la dosis; no es una cura; consulte a un profesional.
    ¿Qué debo buscar en los probióticos para lactantes?
    Cepas claramente identificadas, recuentos viables hasta la fecha de caducidad, formulación adecuada para la edad y una marca confiable.
    ¿Existen riesgos al administrar probióticos a lactantes o niños?
    Generalmente seguros para lactantes sanos, pero existen riesgos en prematuros, inmunocomprometidos o enfermos; usar bajo supervisión médica.
    ¿Debería considerar una prueba del microbioma para mi hijo con eczema?
    Una prueba puede ofrecer indicios, pero no es un diagnóstico; puede guiar estrategias adicionales.
    ¿Qué es InnerBuddies y qué puede decir la prueba?
    InnerBuddies es una prueba de microbioma para lactantes/niños; los resultados pueden ayudar a entender patrones de la eje intestino–piel y adaptar estrategias, pero no es un diagnóstico por sí solo.
    Si el microbioma está involucrado, ¿qué se puede hacer en casa?
    Pasos prácticos: apoyo a la lactancia, dieta equilibrada para la madre que amamanta, evitar antibióticos innecesarios, cuidado suave de la piel, discutir probióticos/prebióticos con un profesional.
    ¿Cómo se relacionan la regulación inmunitaria y la barrera de la piel con la eczema?
    La eczema está relacionada con la regulación inmunitaria y la integridad de la barrera; los microbios intestinales pueden influir en vías reguladoras y metabolitos como los SCFA.
    ¿El objetivo de las estrategias basadas en el microbioma es curar la eczema o reducir los síntomas?
    El objetivo es apoyar la regulación inmunitaria y la barrera y potencialmente reducir la frecuencia y severidad de brotes; no es una cura.
    ¿Cómo puede la dieta o las decisiones alimentarias influir en el microbioma intestinal y la eczema?
    La alimentación temprana influye en el desarrollo del microbioma; la lactancia favorece una microbiota diversa. Consulte con un profesional sobre opciones dietéticas.

    Hear from our satisfied customers!

    • "I would like to let you know how excited I am. We had been on the diet for about two months (my husband eats with us). We felt better with it, but how much better was really only noticed during the Christmas vacations when we had received a large Christmas package and didn't stick to the diet for a while. Well that did give motivation again, because what a difference in gastrointestinal symptoms but also energy in both of us!"

      - Manon, age 29 -

    • "Super help!!! I was already well on my way, but now I know for sure what I should and should not eat, drink. I have been struggling with stomach and intestines for so long, hope I can get rid of it now."

      - Petra, age 68 -

    • "I have read your comprehensive report and advice. Many thanks for that and very informative. Presented in this way, I can certainly move forward with it. Therefore no new questions for now. I will gladly take your suggestions to heart. And good luck with your important work."

      - Dirk, age 73 -